Alnylam Pharmaceuticals: UBS cuts target price to $354 from $550
ALNY•UBS cut its target price for Alnylam Pharmaceuticals to $354 from $550.
Related News
Nasdaq trade halt continues; reason not available at 10:41 a.m.
UCFIW•
iPower opens new AI era with five-year services LOI targeting $21.90 million in potential annualized services
IPW•
German government reportedly plans partnership with Nvidia on AI
NVDA•
US stocks fall as hotter inflation fuels rate-hike concerns, NAGA Group says
SPY•
US yields fall as investors look for safety and bet on pause in rate hikes
TLT•